ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1752	National Cancer Institute	Html	en	Common Moles, Dysplastic Nevi, and Risk of Melanoma	A fact sheet about moles and how some moles may be related to melanoma, the most serious type of skin cancer. Includes photos of differences between moles and cancer.	skin cancer 0.396204 new pencil eraser 0.340631 new mole 0.324515 people—have common moles 0.296925 areas 0.255107 Cancer Statistics Review 0.258106 skin surface 0.252994 American Cancer Society 0.291862 dysplastic nevi 0.760688 ABCDE features 0.255948 shape 0.300226 normal moles 0.26535 melanoma 0.905882 new moles 0.27436 distinct edge 0.298497 UV radiation 0.254044 mole look 0.348624 early melanoma 0.368768 color changes 0.261127 following changes 0.256625 moderately increased chance 0.26864 dysplastic nevus 0.99874 dark skin 0.328273 skin damage 0.265216	new colored area 0.350978 mole changes 0.343324 skin 0.706105 people—develop melanoma 0.334635 cancer cells 0.262185 sun 0.303017 atypical mole 0.288433 National Cancer Institute 0.258053 frequent skin exam 0.273598 common moles 0.677867 chance 0.337967 greater chance 0.265511 American adults—about 0.256684 surface texture 0.317122 Evolving. The mole 0.285916 people 0.632361 doctor 0.289469 normal skin tone 0.268972 family history 0.256672 early melanoma detection 0.355222 unusual mole 0.314622 common mole 0.732427 common mole look 0.339723 fair skin 0.271925	CLICK HERE
1789	National Cancer Institute	Html	es	Complicaciones gastrointestinales (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del estreñimiento, impacción, obstrucción intestinal y diarrea como complicaciones del cáncer o su tratamiento. Se discute el manejo de estos problemas.	PDQ Complicaciones 0.530388 pelvis causa inflamación 0.572317 siguientes procedimientos 0.608568 hormona tiroidea 0.545669 siguientes aspectos 0.533891 Lactobacillus acidophilus 0.526037 rayos x 0.532507 media hora 0.541392 diarrea aguda 0.693188 largo plazo 0.569789 siguientes preguntas 0.540731 Busque privacidad 0.543195 productos lácteos 0.560479 medicamentos iv 0.544267 siguientes indicaciones 0.527177 tratamiento quizás 0.572007 vía iv 0.522455 cáncer.ampliar colonoscopia 0.551466 Instituto Nacional 0.536707 Coma porciones 0.524947 heces retenidas 0.545367 intestino.ampliar procedimiento 0.541183 suficiente ejercicio 0.545879 crónica.Obstrucción intestinal aguda 0.64888	pacientes quizás 0.581825 síntomas quizás 0.540102 metabolismo corporal concentración 0.581977 cantidades correctas 0.533739 régimen brat 0.52571 ¿El estreñimiento 0.640368 medicamentos opioides 0.717569 ejercicio lesión 0.545303 gráfico muestra afecciones 0.567465 National Cancer Institute 0.520678 La nutrición 0.589361 alto contenido 0.5222 siguientes signos 0.535436 Physician Data Query 0.576854 enzimas pancreáticas 0.556797 radiación aguda 0.557929 cuerpo).ampliar anatomía 0.552347 Radiografía abdominal 0.535361 suficiente cantidad 0.531328 enteritis aguda 0.993176 siguientes complicaciones 0.586671 obstrucción intestinal aguda 0.803119 cirugía.Algunos medicamentos 0.559484 siguientes pruebas 0.618199	CLICK HERE
1823	National Cancer Institute	Html	es	Tratamiento del sarcoma de tejido blando en adultos (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento del sarcoma de tejido blando en adultos.	Scandinavian Sarcoma Group 0.539831 Lippincott Williams 0.562481 bEl tumor 0.509518 Compton CC 0.522215 Cancer Institute Surveillance 0.506324 Antonescu CR 0.5084 Sarcoma Group 0.551693 Sin embargo 0.587887 tumor center 0.509169 observación versus 0.507069 largo plazo 0.5106 7th ed 0.522519 DeVita VT Jr 0.615914 from sarcomas 0.514899 Tumores osteocondrales.Condrosarcomas 0.512024 Prognostic factors 0.507702 lymph nodes 0.507203 Rosenberg SA 0.558836 T1b Tumor 0.509623 tumor lipomatoso atípico 0.511636 soft tissue sarcoma 0.94016 Lawrence TS 0.559677 fibroso maligno 0.507755 Cancer Centers Sarcoma 0.522459 localised limb soft 0.508432	sarcoma patients 0.519354 metastasis from soft 0.508028 Tumores vasculares.Hemangioendotelioma 0.512057 O'Sullivan B 0.529169 tratamiento adyuvante versus 0.512692 versus quimioterapia 0.510953 Malawer MM 0.508085 Nielsen T 0.507472 Tumores adipocíticos.Liposarcoma 0.51216 Cancer Staging Manual 0.545483 Maki RG 0.50832 potencial metastásico 0.508732 recidivas locales 0.527298 New York 0.519322 9th ed 0.564335 high risk soft 0.507723 adult soft tissue 0.530167 Byrd DR 0.520996 T2b Tumor 0.50961 mutación genética ptc 0.506056 Helman LJ 0.508415 Sarcoma Group study 0.521636 Molecular biology 0.507762 AJCC Cancer Staging 0.547586	CLICK HERE
1851	National Cancer Institute	Html	es	Tratamiento del cáncer de tiroides (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento del cáncer de tiroides.	siguientes procedimientos 0.422153 hormona tiroidea 0.492622 bLos ganglios 0.448367 Hürthle cell carcinoma 0.418971 mínima diseminación 0.464789 T4b Enfermedad 0.438377 American Cancer Society 0.43686 European Thyroid Association 0.427771 thyroid disease 0.486942 niveles i 0.45199 Thyroid Association 0.441602 fase iii 0.434728 Natl Cancer Inst 0.440945 Thyroid calcification 0.433055 thyroid with 0.432277 Prognostic factors 0.431082 ≤2 cm 0.731745 patients with 0.416562 tiroides estadio 0.461688 N1a Metástasis 0.590742 N1b Metástasis 0.55338 American Thyroid Association 0.427447 papillary thyroid carcinoma 0.534329 tejidos blandos peritiroideos 0.507165 glándula tiroides 0.891491	tumores papilares 0.421501 nivel vii 0.450974 Lennard CM 0.428158 tiroides tipo 0.453807 ablación tiroidea 0.436707 French Thyroid Cancer 0.436044 M0 T1 0.439686 thyroid cancer 0.993324 cápsula tiroidea 0.541937 thyroid carcinoma with 0.448553 tejidos blandos subcutáneos 0.474653 differentiated carcinoma 0.433423 follicular thyroid carcinomas 0.439446 thyroid carcinoma depends 0.445887 thyroid carcinomas 0.753573 Surg Oncol 0.439117 pronóstico adverso 0.424396 cartílagos tiroides 0.469208 Thyroid tumors 0.433 estadios tnm 0.421127 American Joint Committee 0.423622 ganglios linfáticos retrofaríngeos 0.70543 lobectomía tiroidea 0.423995 AJCC Cancer Staging 0.417512	CLICK HERE
1873	National Cancer Institute	Html	es	Tratamiento del sarcoma uterino (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento del sarcoma uterino.	Obstet Gynecol 0.426292 Major FJ 0.422403 sarcomas uterinos 0.471793 cisplatin as 0.411109 Markman M 0.40448 gynecologic cancer 0.405911 prognostic factors 0.405684 Brunetto VL 0.40512 Sin embargo 0.405423 or without paclitaxel 0.411277 fase ii 0.413551 Ifosfamide treatment 0.404047 endometrial stromal sarcoma 0.415162 Radiat Oncol Biol 0.40725 siguientes puntos 0.405418 oncology group study 0.684258 stromal sarcomas previously 0.409618 patología equivocada 0.404764 Barrett RJ 0.404588 Kilgore L 0.404374 recurrent or metastatic 0.405758 mixed mesodermal tumors 0.448955 Gynecologic Oncology Group 0.969258 Gynecol Oncol 0.445429 Filiaci V 0.404525	Beecham J 0.404572 or recurrent leiomyosarcoma 0.405872 Blessing JA 0.5678 meses vs 0.434084 Organización Mundial 0.408363 pilot study 0.40409 sarcomas mesodérmicos mixtos 0.406902 Smith MR 0.405644 as second-line chemotherapy 0.406079 or recurrent 0.412147 New York 0.404218 Peters WA 0.405698 Clin Oncol 0.49692 combination chemotherapy 0.409211 verdaderos sarcomas 0.414072 Oncol Biol Phys 0.407314 cuerpo uterino 0.408492 elementos homólogos 0.406306 estadio iii 0.405213 Rosenshein N 0.4046 stromal sarcoma 0.431127 Homesley HD 0.404643 dimethyl triazenoimidazole carboxamide 0.404595 with or without 0.432244	CLICK HERE
2001	National Cancer Institute	Html	es	Familiares a cargo de pacientes de cáncer: funciones y desafíos (PDQ®)–Versión para profesionales de salud	Sumario informativo revisado por expertos acerca de los desafíos que enfrentan los familiares a cargo de los pacientes con cáncer. Este resumen se centra en las funciones típicas y las inquietudes de las personas a cargo del paciente y en las intervenciones útiles para esas personas.	etapa final 0.435131 Cancer Communication Assessment 0.482566 giving bad news 0.42261 to breast 0.424042 Sin embargo 0.471583 receiving palliative care 0.419812 American Cancer Society 0.47018 Family support 0.41866 family to breast 0.421621 CA Cancer 0.459636 Given BA 0.442227 Communication Assessment Tool 0.434693 Rose JH 0.438883 family meetings 0.426208 Estados Unidos 0.421866 Support Care 0.447919 Caregivers Based 0.422755 Palliat Care 0.44789 patients with 0.44256 Pain Symptom Manage 0.455568 Support Oncol 0.41857 Baile WF 0.422726 Family Caregiver Support 0.426151 family caregivers 0.94013 Crit Care Nurs 0.421936	Oncol Nurs Forum 0.49008 with family caregivers 0.435774 Care Cancer 0.474055 Cancer Facts 0.43863 Arnold RM 0.422137 palliative care 0.565514 Hosp Palliat Care 0.420581 paciente cumpla 0.459325 terminally ill patients 0.428058 Family caregiver quality 0.42241 communication skills 0.434733 cancer pain 0.552042 Crit Care 0.427432 Palliat Med 0.438559 Given CW 0.427811 breast cancer 0.524972 Arch Intern Med 0.454734 Conducting family meetings 0.417671 Baider L 0.421555 caregivers with 0.421979 placing family meetings 0.417694 Crit Care Med 0.422158 symptoms among caregivers 0.425057 cancer communication 0.540368	CLICK HERE
2026	National Cancer Institute	Html	es	Prevención del cáncer colorrectal (PDQ®)–Versión para profesionales de salud	Sumario de información revisada por expertos sobre factores que influyen en el riesgo de presentar cáncer colorrectal y sobre las investigaciones dirigidas a la prevención de esta enfermedad.	colorectal adenoma chemoprevention 0.338068 colorectal neoplasia among 0.319011 long-term risk 0.313313 Adults With Colorectal 0.319346 Sin embargo 0.339382 Gastrointest Endosc 0.311269 largo plazo 0.32477 CPS II 0.314437 flexible sigmoidoscopy screening 0.31731 Preventive Services Task 0.332229 colorectal cancer 0.908646 population-based study 0.314294 Estados Unidos 0.331084 Natl Cancer Inst 0.334301 Women's Health Study 0.324602 after colonoscopy 0.309105 CCR multivariantes 0.345859 Aspirin Trial 0.311104 Women's Health Initiative 0.338408 colorectal adenomatous polyps 0.317676 Health Initiative 0.348288 colorrectal hereditario 0.317986 Women's Health 0.346194 cancer prevention 0.326424 Rothwell PM 0.314674	colorectal adenoma 0.357654 Health Study 0.364941 sporadic colorectal adenomas 0.324242 RR multivariante 0.309686 CCR clínico 0.37477 Health Study Research 0.310687 left-sided colorectal neoplasms 0.31858 primary prevention 0.311318 Hereditary Cancer Syndromes 0.314398 Epidemiol Biomarkers Prev 0.320559 arteriopatía coronaria 0.30952 riesgo promedio 0.330242 antecedentes familiares 0.330027 Cancer Prevention Study 0.318847 Intern Med 0.471733 cohort study using 0.309014 Clin Oncol 0.310431 Services Task Force 0.331368 systematic review 0.369209 Giovannucci E 0.31569 physical activity 0.319835 Protection from 0.309663 Women’s Health Initiative 0.324227 with colorectal cancer 0.348991	CLICK HERE
15777	National Cancer Institute	Html	en	Research Directions for Childhood Cancer	NCI has identified areas for which more research is needed on childhood cancers, including investments in basic research, immunotherapies, and moleculary targeted therapies.	small molecule inhibitors 0.412891 childhood cancers 0.94672 critical gaps 0.332101 major treatment advance 0.412137 Pediatric MATCH 0.392576 research proposals 0.436951 peer review process 0.389826 immunotherapy technique 0.352473 NCI scientists Lawrence 0.622389 chimeric antigen receptor 0.460833 cancer cells 0.401044 highly trained scientists 0.390662 high-priority goal 0.343491 cancer research 0.527941 best scientific proposals 0.421088 pediatric patients 0.416725 pediatric cancer 0.412777 research areas 0.34678 T-cell receptor 0.362608 specific disease area 0.405285 clinical trials 0.669991 immunotherapy treatments 0.349585 NCI leadership 0.495193 Tumor DNA sequencing 0.405564	Pediatric Brain Tumor 0.687267 NCI-COG Pediatric Molecular 0.487101 NCI-sponsored clinical trials 0.416329 cancer immunology 0.348212 research funding decisions 0.424865 NCI funding opportunities 0.589573 rigorous grant application 0.388949 NCI portfolio 0.493947 rapidly advancing field 0.423802 new approaches 0.32698 advanced cancers 0.402816 research topic 0.333717 Pediatric Oncology Branch 0.692641 young adult patients 0.616776 NCI 0.771754 Children’s Oncology 0.432835 research category 0.33728 Brain Tumor Consortium 0.615122 Oncology Group 0.433591 NCI’s Steven 0.52013 past decade 0.330224 NCI Center 0.621549 adoptive cell transfer 0.42055	CLICK HERE
16644	National Cancer Institute	Html	es	Régimen Gonzalez (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos sobre el uso del régimen Gonzalez como tratamiento para personas con cáncer. Nota: La información contenida en este sumario ya no se actualiza y se ofrece solo con fines de consulta.	Life Sci 0.504011 Chabot JA 0.503454 efectos antineoplásicos directos 0.502996 enzima pancreática porcina 0.506836 revisión externa journal 0.505701 Isenman L 0.503932 Krebs ET 0.503536 with gemcitabine-based chemotherapy 0.507748 Isaacs LL 0.521605 Clinical Pearls News 0.516873 enzimas pancreáticas porcinas 0.512289 estudio clínico 0.503404 Rothman S 0.503859 Fine RL 0.5034 William Donald Kelley 0.502696 Instituto Nacional 0.515061 enzyme treatment 0.536871 Aliaga C 0.503794 Gonzalez NJ 0.605468 with nutrition 0.522734 Estados Unidos 0.511805 mammary tumor metastasis 0.507989 Moneychanger July 0.504705 Clinical Oncology Article 0.50262 Liebow C 0.503937	Gonzalez Regimen 0.511241 Cancer Coalition 0.503421 enzimas digestivas intactas 0.50677 Tsai WY 0.503533 Nutr Cancer 0.527006 PDQ Régimen Gonzalez 0.516804 enzimas pancreáticas otc 0.512028 National Cancer Institute 0.503592 treatment with 0.503692 diet therapy 0.502711 accessed april 0.540709 complejo tratamiento 0.503552 Gonzalez Nicholas 0.510997 Clin Oncol 0.503748 Kelley WD 0.504653 enzimas pancreáticas 0.789985 régimen gonzalez 0.975131 suplementos alimentarios otc 0.504496 tumor mamario murino 0.502751 Pittman B 0.503853 torrente circulatorio 0.504682 Moneychanger interview 0.504631 Pearls News November 0.516553 Nicholas Gonzalez 0.53567	CLICK HERE
16811	National Cancer Institute	Html	es	Cartílago (bovino y de tiburón) (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos sobre el uso de cartílago bovino y de tiburón como tratamiento para personas con cáncer. Nota: la información contenida en este sumario ya no se actualiza y se ofrece solo con fines de consulta.	Shirai E 0.323137 cancer treatment 0.318107 relation with cartilage-derived 0.318214 Langer R 0.391189 Enomoto M 0.357345 Prudden JF 0.438802 Biol Chem 0.333806 shark cartilage 0.967013 shark cartilage with 0.323621 Biol Response Mod 0.535917 Cartilage-derived growth factor 0.322107 tumor angiogenesis 0.329827 cultured endothelial cells 0.316222 Cancer Res 0.3293 inhibitor from shark 0.3338 Natl Cancer Inst 0.381802 novel shark cartilage 0.322776 shark cartilage extract 0.362678 with cartilage-derived anti-tumor 0.3188 powdered shark cartilage 0.321655 Japanese shark cartilage 0.32145 with cartilage-derived 0.324288 Biophys Res Commun 0.316215 Biochem Biophys Res 0.31677 inhibits tumor neovascularization 0.319919	Biol Int Rep 0.323384 stem cell 0.318383 potent shark cartilage-derived 0.318104 Takigawa M 0.353102 tumor growth 0.323007 cartilage extract 0.364849 anti-angiogenic antitumor factor 0.318413 stem cell assay 0.317911 Cell Biol Int 0.327732 its relation with 0.316418 cell line produces 0.317193 Exp Med Biol 0.323654 from cartilage 0.324423 shark cartilage-derived angiogenesis 0.320509 New York 0.316148 antitumor factor 0.334004 endothelial cell 0.365475 Cell Biol 0.339136 cartílago bovino 0.480214 cartilage contains inhibitors 0.320628 angiogenesis inhibitor from 0.364307 from shark cartilage 0.349703 Sudhalter J 0.330756 from japanese shark 0.31927	CLICK HERE